The largest database of trusted experimental protocols
> Procedures > Educational Activity > Test Preparation

Test Preparation

Discover the optimal test preparation strategies with PubCompare.ai.
This AI-powered platform helps researchers streamline their research process and enhance the reproducibility of their results.
Easily locate test preparation protocols from literature, preprints, and patents, and leverage AI-driven comparisons to identify the best protocols and products for your specific needs.
Improve the quality of your research outcomes by accessing a comprehensive resource of test preparation methods and techniques.
Simplify your test preparation workflow and elevate the impact of your work with PubCompare.ai.

Most cited protocols related to «Test Preparation»

Measurements took place at the ESPRIT Arena (Duesseldorf, Germany, see Fig 1 for a visualisation of the test setup on-site). Twenty male soccer players (age: 22.9±3.6 years, height: 180.1±5.9 cm, body mass: 73.5±5.3 kg) playing for the German Mittelrheinliga team TSC Euskirchen participated in the study. Prior to participation, all players received comprehensive verbal and written explanations of the study, which was conducted within a period of two consecutive days. On each day, ten players participated. Players completed an individually selected warm-up before commencement of the tasks. Players were instructed to give maximal effort in all tasks. All players provided voluntarily signed informed consent to wear VICON markers and to participate in the collection of spatiotemporal tracking data. Institutional board approval for the study was obtained from the Ethics Committee of the Technical University of Munich. All performance data were anonymized to ensure confidentiality. This study conformed to the recommendations of the Declaration of Helsinki.
Full text: Click here
Publication 2020
Esapent Ethics Committees Human Body Males Test Preparation
Original data were used from five studies in PCHC (this system is open to all children in the Netherlands from birth to the age of 19 years) and from three curriculum innovation studies in primary and secondary schools. Four of these studies examined the national implementation of PCHC guidelines, and the other four focussed on the implementation of health promotion interventions. Table 1 provides a brief description of the eight empirical studies. Different study designs were used. In order to have comparable data, only cross-sectional data were used, meaning that both determinants and the use of the innovation were measured simultaneously. In case determinants and use were measured in both the pre-test and post-test(s), we only used the pre-test measurements.

Description of the eight empirical studies in the meta-analysis

Type of studySettingDesignRespondentsN
Guideline for visual disorders: levels of use [18 ]PCHCCross sectionalDoctors, nurses, doctor's assistanta311
Guideline for congenital heart disorders: levels of use [19 ]PCHCCross sectionalDoctors, nursesa210
Guideline for prevention of child abuse: effect of planned innovation strategy on levels of use [20 ]PCHCPre-test and post-testc; experimental vs. control groupDoctors, nursesb302
Guideline for congenital heart disorders: effect of e-learning vs. traditional learning on levels of use [21 ]PCHCPre-test and post-testc; experimental vs. control groupDoctors, nursesb317
Education programme for prevention of passive smoking in infants: levels of continuation of use [22 (link)]PCHCCross sectionalDoctors, nursesa465
School-wide programme for prevention of bullying: effect of planned innovation strategy on levels of usedPrimary schoolsPre-test and post-testcTeachersb125
Mental health promotion programme: effect of planned innovation strategy on levels of usedPrimary schoolsPre-test and two post-testscTeachersb188
Sex education programme: effect of planned innovation strategy on levels of use [23 (link)]Secondary schoolsPre-test and post-testc; experimental vs. control groupTeachersb59
Total1977

PCHC, Preventive Child Health Care.

aAll PCHC organizations.

bSelected sample of PCHC organizations/schools.

cWe only used pre-test measurements.

dPublication in preparation.

Publication 2014
Abuse, Child Child Child, Preschool Childbirth Congenital Disorders Health Promotion Heart Heart Diseases Infant Nurses Preventive Health Programs Preventive Health Services Programmed Learning Smoking Prevention Test Preparation Wellness Programs

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2020
Antibodies Antigens Biohazards Biological Assay Biological Markers Buffers Child Clinical Laboratory Services Communicable Diseases COVID 19 Cross Reactions Diagnosis Dimercaprol DNA, Complementary DNA, Double-Stranded Donors Emergencies Enzymes Fluorescent Dyes Food Gene Amplification Gene Products, env Genes Genes, vif Genes, Viral Genome Gold Health Personnel Human Body Hydrolysis Hypersensitivity Immunoglobulins Infection Membrane Proteins Nasopharynx Nose Nucleic Acids Nucleocapsid Nucleocapsid Proteins Oligonucleotide Primers Oropharynxs Pandemics Parts, Body Patients Pharmaceutical Preparations Pharynx Plasma Quarantine Real-Time Polymerase Chain Reaction Rectum Respiratory Rate Respiratory System Reverse Transcriptase Polymerase Chain Reaction Reverse Transcription RNA, recombinant RNA-Directed RNA Polymerase RNase P Safety Saline Solution Sarbecovirus SARS-CoV-2 Severe acute respiratory syndrome-related coronavirus Specimen Collection spike protein, SARS-CoV-2 Sputum Test Preparation Tests, Serologic Viral Genome Virus Virus Diseases
The methodology for measuring endothelial function and vascular reactivity using DTM has been previously described [21 (link)–25 (link)]. All DTM tests were performed using a VENDYS® 6000 Portable System (Endothelix, Houston, TX), a PC-based system that fully automates the cuff reactive hyperemia protocol. The general test setup and a sample VENDYS test report are shown in Figure 1. During subject preparation, blood pressure cuffs were placed on both of the subject's upper arms, and VENDYS skin temperature sensors were affixed to both of the subject's index fingers. The software-driven DTM test began with an automated measurement of blood pressure and heart rate obtained from the left arm cuff. Following a 5-minute period of patient and temperature stabilization, a 5-minute cuff occlusion (cuff inflated to 30 mmHg above systolic BP) of the right arm was performed. During the cuff occlusion period, fingertip temperature in the right hand decreased because of the absence of warm circulating blood. When the cuff was released after the 5-minute occlusion, hyperemic blood flow to the forearm and hand was restored, and this resulted in a “temperature rebound” in the fingertip that is directly related to the subject's hyperemic blood flow response, endothelial function, and vascular reactivity [21 (link), 22 (link)]. Using the recorded fingertip temperatures, the ambient temperature of the testing room, the observed slope of temperature decline, and a multivariate bioheat formula, the VENDYS software calculated and plotted a zero reactivity curve (ZRC). The ZRC served as an internal control and showed the expected temperature rebound curve, if zero vascular reactivity was present and the other variables remained the same. In other words, the ZRC is the expected temperature curve, if no vasodilatation and subsequent reactive hyperemia had occurred [21 (link)]. Vascular reactivity index (VRI) was determined by taking the maximum difference between the observed temperature rebound curve and the ZRC during the reactive hyperemia period. VRI ranged from 0.0 to 3.5 and was classified as being indicative of poor (0.0 to <1.0), intermediate (1.0 to <2.0), or good (≥2.0) vascular reactivity.
The VENDYS DTM Test Registry includes age, sex, blood pressure, heart rate, VRI, and fingertip temperature measurements recorded during DTM tests. The Registry does not include other health related information. All DTM tests were performed in ambulatory care clinical settings. This study includes a total of 6,084 patients from 18 clinics that volunteered to submit their data to the Registry. The number of each type of medical practice is as follows: cardiology = 9, general/family practice = 4, antiaging = 3, and internal medicine = 2.
Statistical analyses were performed using MATLAB (The MathWorks, Inc., Natick, MA). Variable data were expressed as mean ± SD. VRI scores in men and women were compared using unpaired Student's t-test. Comparisons of categorical data (e.g., proportion of subjects with good VRI in men versus women) were performed using Fisher's exact test. Pairwise correlations were examined using Pearson's correlation coefficient, and correlations between VRI and multiple patient characteristics (i.e., age, sex, blood pressure, and heart rate) were evaluated using multiple linear regression analysis. p value < 0.05 was considered significant. When performing statistical comparisons, tests with missing data were excluded from the comparison. “Cold Finger Flag” was defined as the condition in which the right finger temperature at start of cuff occlusion (time 300 s) is ≤27°C. Previous DTM testing had shown that right finger t300 temperatures < 27°C often resulted in technically poor results. “Sympathetic Response Flag” was defined as the condition in which left finger temperature continuously declines (>0.5°C temperature drop over a 5-minute time period) after right arm-cuff occlusion. When evaluating VRI, tests that exhibited “Cold Finger Flag” (n = 353) or “Sympathetic Response Flag” (n = 294) were excluded from the analyses. In addition to monitoring temperature at the index finger of the right arm, we studied temperature changes at the index finger of the left (nonoccluded) arm and observed interesting signals that are currently under further investigations and not included in the results below.
Full text: Click here
Publication 2016
BLOOD Blood Circulation Blood Pressure Blood Vessel Body Temperature Changes Cardiovascular System Care, Ambulatory Cold Temperature Dental Occlusion Determination, Blood Pressure Endothelium Fingers Forearm Hyperemia Patients Rate, Heart Reactive Hyperemia Skin Temperature Systolic Pressure Test Preparation Vasodilation Woman
To test the efficiency of AliGROOVE we designed two sets of nucleotide and amino acid sequence data using 4-taxon and 6-taxon trees (Figure 1). The topology of the 4-taxon setup (setup A, Figure 1a) contained two long branches of unrelated taxa (with branch lengths BL 2 = 0.1,0.3,0.5,0.7,0.9,1.1,1.3,1.5) under three different branch length conditions for the other two short terminal branches (BL 3 = 0.1,0.12,0.14 and RB = 0.1) and two different lengths of the short internal branch (BL 1 = 0.01,0.02). The 6-taxon setup (setup B, Figure 1b) contained two long internal branches (BL 2 = 0.1,0.3,0.5,0.7,0.9,1.1,1.3,1.5), separated by a short internal branch (BL 1 = 0.01) while the lengths of terminal branches are kept constant (BL 3 = 0.01 and RB = 0.1). For both test setups, 100 alignments were generated for each step of BL 2 branch elongation. Sequence length of each alignment of setup A was set to 250,000 character state positions and for setup B to 50,000 character state positions to reduce the calculation time. All alignments were generated with INDELible v.1.03 [24 (link)]. In order to simulate nucleotide sequence data we used the Jukes-Cantor model (JC) of sequence evolution and for amino acid sequence data the BLOSUM62 substitution model. All data were simulated with among site rate variation (ASRV), using a mixed-distribution model with a shape parameter α = 1.0, and a proportion of invariant sites ρinv= 0.3. ASRV was modelled using a continuous Γ-rate distribution while indel events were not simulated.
Trees of simulated data were inferred with PhyML_3.0_linux64 [25 (link), 26 (link)]. We analyzed the data with a mixed-distribution model (JC+ Γ + I) and correct parameter values (α = 1.0, ρinv= 0.3), except for the categorization of the gamma distribution. The number of relative substitution rate categories was set to four (c = 4) and tree topologies and branch lengths were optimized. Maximum Likelihood analyses were performed and evaluated with a Perl pipeline. For each branch length-combination, we generated 100 data replicates and recorded the frequencies of correct and incorrect tree reconstructions using correct alignments and nearly correct substitution models (Figures 2, 3, Additional files 1, 2, 3).
Full text: Click here
Publication 2014
A-A-1 antibiotic Amino Acid Sequence Biological Evolution Cantor Character Gamma Rays INDEL Mutation Nucleotides Reconstructive Surgical Procedures Sequence Alignment Test Preparation Trees

Most recents protocols related to «Test Preparation»

Not available on PMC !

EXAMPLE 48

In order to determine B7-1 competition efficiency of CTLA4 binding Nanobodies, the purified clones were tested in an ELISA competition assay setup.

In short, 2 μg/ml B7-1-muFc (Ancell, Bayport, MN, US, Cat #510-820) was immobilized on maxisorp microtiter plates (Nunc, Wiesbaden, Germany) and free binding sites were blocked using 4% Marvel in PBS. Next, 0.33 nM CTLA4-hFc was mixed with a dilution series of purified Nanobody. An irrelevant Nanobody (1A1) was used as a negative controle, since this Nanobody does not bind to CTLA4. As a positive controle for competition with B7-1, the commercial CTLA-4 binding antibody (BNI-3; competing for B7-1 and B7-2) was used. After incubation and a wash step, the CTLA4-hFc was detected with a HRP-conjugated anti-human Fc (Jackson Immunoresearch Laboratories, West Grove, PA, US, Cat #109-116-170) 1:1500 in 2% MPBST. OD values obtained, depicted in FIGS. 26 and 27, show that 2 Nanobodies selected show competition with B7-1 for binding to CTLA4 in a dose-dependent manner.

Full text: Click here
Patent 2024
Binding Sites Biological Assay Clone Cells CTLA4 protein, human Enzyme-Linked Immunosorbent Assay Figs Homo sapiens Immunoglobulins Psychological Inhibition Technique, Dilution Test Preparation VHH Immunoglobulin Fragments
Not available on PMC !

EXAMPLE 49

In order to determine B7-2 competition efficiency of CTLA4 binding Nanobodies, the purified clones were tested in an ELISA competition assay setup.

In short, 5 μg/ml B7-muFc (Ancell, Bayport, MN, Cat #509-820) was immobilized on maxisorp microtiter plates (Nunc, Wiesbaden, Germany) and free binding sites were blocked using 4% Marvel in PBS. Next, 22 nM CTLA4-hFc was mixed with a dilution series of purified Nanobody. An irrelevant Nanobody (1A1) was used as a negative controle, since this Nanobody does not bind to CTLA4. As a positive controle for competition, the commercial CTLA-4 binding antibody (BNI-3; competing for B7-1 and B7-2) was used. After incubation and a wash step the CTLA4-hFc was detected with a HRP-conjugated anti-human Fc (Jackson Immunoresearch Laboratories, West Grove, PA, US, Cat #109-116-170) 1:1500 in 2% MPBST. OD values obtained, depicted in FIGS. 28 and 29, show that 4 Nanobodies selected show competition with B7-2 for binding to CTLA4 in a dose-dependent manner.

Full text: Click here
Patent 2024
Binding Sites Biological Assay Clone Cells CTLA4 protein, human Enzyme-Linked Immunosorbent Assay Figs Homo sapiens Immunoglobulins Psychological Inhibition Technique, Dilution Test Preparation VHH Immunoglobulin Fragments

EXAMPLE 40

In order to determine B7-1 competition efficiency of CD28 binding Nanobodies, the purified Nanobodies that showed binding in the previous binding assay were tested in an ELISA competition assay setup.

In short, 1 μg/ml B7-1-muFc (Ancell, Bayport, MN, US, Cat #510-820) was immobilized on maxisorp microtiter plates (Nunc, Wiesbaden, Germany) and free binding sites were blocked using 4% Marvel in PBS. Next, 2 μg/ml CD28-hFc was mixed with a dilution series of purified Nanobody. An irrelevant Nanobody against FcgR1 (49E4) was used as a negative controle, since this Nanobody does not bind to CD28. After incubation and a wash step the CD28-hFc was detected with a HRP-conjugated anti-human Fc (Jackson Immunoresearch Laboratories, West Grove, PA, US, Cat #109-116-170) 1:1500 in 2% MPBST. The results are shown in FIG. 22. All Nanobodies selected showed competition with B7-1 for binding to CD28 in a dose-dependent manner.

Full text: Click here
Patent 2024
Binding Sites Biological Assay Enzyme-Linked Immunosorbent Assay Homo sapiens Technique, Dilution Test Preparation Titrimetry VHH Immunoglobulin Fragments
Not available on PMC !

EXAMPLE 21

In order to determine PD-1 competition efficiency of B7-H1 binding Nanobodies, the positive clones of the binding assay were tested in an ELISA competition assay setup.

In short, 2 μg/ml B7-H1 ectodomain (rhB7H1-Fc, R&D Systems, Minneapolis, US, Cat #156-B7) was immobilized on maxisorp microtiter plates (Nunc, Wiesbaden, Germany) and free binding sites were blocked using 4% Marvel in PBS. Next, 0.5 μg/ml of PD-1-biotin was preincubated with 10 μl of periplasmic extract containing Nanobody of the different clones and a control with only PD-1-biotin (high control). The PD-1-biotin was allowed to bind to the immobilized ligand with or without Nanobody. After incubation and a wash step, PD-1 binding was revealed using a HRP-conjugated streptavidine. Binding specificity was determined based on OD values compared to controls having received no Nanobody (high control). OD values for the different Nanobody clones are depicted in FIG. 12.

Full text: Click here
Patent 2024
Binding Sites Biological Assay Biotin biotin 1 CD274 protein, human Clone Cells Enzyme-Linked Immunosorbent Assay Ligands Periplasm Psychological Inhibition Test Preparation VHH Immunoglobulin Fragments
Not available on PMC !

EXAMPLE 16

In order to determine competition efficiency of PD-1 binding Nanobodies, the positive clones of the previous binding assay were tested in an ELISA competition assay setup.

In short, 2 μg/ml PD-1 ectodomain (R&D Systems Cat #1086-PD, Minneapolis, US) was immobilized on maxisorp microtiter plates (Nunc, Wiesbaden, Germany) and free binding sites were blocked using 4% Marvel in PBS. Next, 0.5 μg/ml of biotinylated PD-L2 or B7-H1 was preincubated with a dilution series of purified Nanobody. An irrelevant Nanobody against FcgR1 (49C5) was used as a negative controle, since this Nanobody does not bind to PD-1. PD-L2 or B7-H1 without biotin (cold PD-L2 or cold B7-H1) was used as a positive controle for competition. The results are shown in FIGS. 9 and 10. 4 Nanobody families show competition with PD-L2-biotin for binding to PD-1 in a dose-dependent matter. The same 4 Nanobody families also show competition with B7-H1-biotin for binding to PD-1 in a dose-dependent manner.

Full text: Click here
Patent 2024
Binding Sites Biological Assay Biotin CD274 protein, human Clone Cells Cold Temperature Enzyme-Linked Immunosorbent Assay Figs Technique, Dilution Test Preparation Titrimetry VHH Immunoglobulin Fragments

Top products related to «Test Preparation»

Sourced in Germany, Denmark, United States
Maxisorp microtiter plates are a laboratory product designed for various immunoassay applications. The plates feature a high-binding surface that helps optimize the adsorption of proteins, antibodies, and other biomolecules. They are commonly used in techniques such as enzyme-linked immunosorbent assay (ELISA) to facilitate the detection and quantification of target analytes.
Sourced in United States
HRP-conjugated anti-human Fc is a laboratory reagent designed for use in immunoassays. It consists of horseradish peroxidase (HRP) covalently linked to antibodies that specifically recognize the Fc region of human immunoglobulins. This reagent can be used to detect and quantify human antibodies in various experimental settings.
Sourced in United States
RhB7H1-Fc is a recombinant protein that consists of the extracellular domain of the human B7-H1 protein fused to the Fc region of human IgG1. It is used for research purposes.
Sourced in United States, United Kingdom, Germany, Canada, Japan, Sweden, Austria, Morocco, Switzerland, Australia, Belgium, Italy, Netherlands, China, France, Denmark, Norway, Hungary, Malaysia, Israel, Finland, Spain
MATLAB is a high-performance programming language and numerical computing environment used for scientific and engineering calculations, data analysis, and visualization. It provides a comprehensive set of tools for solving complex mathematical and computational problems.
Sourced in United States
The PD-1 ectodomain is a recombinant protein that corresponds to the extracellular domain of the human Programmed Cell Death 1 (PD-1) receptor. PD-1 is an immune checkpoint receptor that negatively regulates T cell activation and function. The PD-1 ectodomain can be used in various immunological and biochemical applications.
Sourced in United States
B7-H2 ectodomain is a recombinant protein that encompasses the extracellular domain of the B7-H2 (ICOSL) protein. B7-H2 is a type I transmembrane protein that functions as a costimulatory molecule involved in the regulation of T-cell activation.
Sourced in United States, Germany, United Kingdom, Italy, Canada, China, Japan, Belgium, France, Spain, Switzerland, Poland, Uruguay, Denmark, Singapore
CellQuest software is a data acquisition and analysis software designed for flow cytometry applications. It provides tools for acquiring, processing, and analyzing flow cytometry data.
Sourced in United States
PD-L2 ectodomain is a recombinant protein that represents the extracellular domain of the human Programmed Death-Ligand 2 (PD-L2) molecule. PD-L2 is a cell surface glycoprotein that functions as a ligand for the PD-1 receptor and plays a role in the regulation of T cell activation and immune responses.
Sourced in United States, Germany, United Kingdom, China, Canada, Japan, Italy, France, Belgium, Switzerland, Singapore, Uruguay, Australia, Spain, Poland, India, Austria, Denmark, Netherlands, Jersey, Finland, Sweden
The FACSCalibur is a flow cytometry system designed for multi-parameter analysis of cells and other particles. It features a blue (488 nm) and a red (635 nm) laser for excitation of fluorescent dyes. The instrument is capable of detecting forward scatter, side scatter, and up to four fluorescent parameters simultaneously.
Sourced in United Kingdom, Germany, United States
GF/C filters are laboratory filter papers designed for general filtration purposes. They are made of glass microfibers and have a nominal pore size of 1.2 microns. GF/C filters are suitable for a variety of filtration applications, including sample preparation, particle retention, and liquid-solid separation.

More about "Test Preparation"

Optimizing Test Preparation Strategies: Unlocking Research Potential with PubCompare.ai Streamlining the Research Process: Test preparation is a critical component of any successful research endeavor, ensuring the reliability and reproducibility of your results.
PubCompare.ai, an AI-powered platform, offers a comprehensive solution to enhance your test preparation workflow.
This innovative tool empowers researchers to easily locate test preparation protocols from a vast repository of literature, preprints, and patents, leveraging advanced AI-driven comparisons to identify the optimal protocols and products for your specific needs.
Enhancing Reproducibility and Quality: Maximizing the quality of your research outcomes is a top priority, and PubCompare.ai is designed to help you achieve this goal.
By providing access to a comprehensive database of test preparation methods and techniques, including insights from Maxisorp microtiter plates, HRP-conjugated anti-human Fc, RhB7H1-Fc, MATLAB, PD-1 ectodomain, B7-H2 ectodomain, CellQuest software, PD-L2 ectodomain, FACSCalibur, and GF/C filters, this platform empowers you to make informed decisions and enhance the reproducibility of your results.
Streamlining Workflow and Elevating Impact: PubCompare.ai simplifies your test preparation workflow, allowing you to focus on the core aspects of your research.
With this AI-powered tool, you can easily navigate the wealth of information, identify the best protocols and products, and optimize your testing procedures.
By leveraging the insights and capabilities of PubCompare.ai, you can elevate the impact of your work and drive your research forward with confidence.
Discover the Power of PubCompare.ai: Unlock the full potential of your research with PubCompare.ai.
Explore the platform, access the comprehensive database of test preparation resources, and leverage the AI-driven comparisons to streamline your workflow and enhance the quality of your research outcomes.
Embark on a journey of discovery and success with this innovative tool at your fingertips.